242 related articles for article (PubMed ID: 23648828)
21. Phase II, Multicenter, Single-arm Trial of Eribulin as First-line Therapy for Patients With Aggressive Taxane-pretreated HER2-Negative Metastatic Breast Cancer: The MERIBEL Study.
Ortega V; Antón A; Garau I; Afonso N; Calvo L; Fernández Y; Martínez-García M; Blanco E; Zamora P; García M; Illarramendi JJ; Rodríguez Sánchez CA; Sampayo M; Aguirre E; Pérez-García JM; Cortés J; Llombart-Cussac A
Clin Breast Cancer; 2019 Apr; 19(2):105-112. PubMed ID: 30679100
[TBL] [Abstract][Full Text] [Related]
22. Are pharmacogenomic biomarkers an effective tool to predict taxane toxicity and outcome in breast cancer patients? Literature review.
De Iuliis F; Salerno G; Taglieri L; Scarpa S
Cancer Chemother Pharmacol; 2015 Oct; 76(4):679-90. PubMed ID: 26198313
[TBL] [Abstract][Full Text] [Related]
23. Classical CMF regimen as adjuvant chemotherapy for triple-negative breast cancer may be more effective compared with anthracycline or taxane-based regimens.
Wang S; Shi Y; Yuan Z; Wang X; Liu D; Peng R; Teng X; Qin T; Peng J; Lin G; Jiang X
Med Oncol; 2012 Jun; 29(2):547-53. PubMed ID: 21528408
[TBL] [Abstract][Full Text] [Related]
24. Relationship between tumour size and response to neoadjuvant chemotherapy among breast cancer patients in a tertiary center in Nigeria.
Samuel O; Olayide A; Ganiyu R; Olufemi H; Halimat A
Malawi Med J; 2018 Mar; 30(1):13-16. PubMed ID: 29868153
[TBL] [Abstract][Full Text] [Related]
25. The efficacy of taxane chemotherapy for metastatic breast cancer in BRCA1 and BRCA2 mutation carriers.
Kriege M; Jager A; Hooning MJ; Huijskens E; Blom J; van Deurzen CH; Bontenbal M; Collee JM; Menke-Pluijmers MB; Martens JW; Seynaeve C
Cancer; 2012 Feb; 118(4):899-907. PubMed ID: 21761396
[TBL] [Abstract][Full Text] [Related]
26. A phase II study of oral enzastaurin in patients with metastatic breast cancer previously treated with an anthracycline and a taxane containing regimen.
Mina L; Krop I; Zon RT; Isakoff SJ; Schneider CJ; Yu M; Johnson C; Vaughn LG; Wang Y; Hristova-Kazmierski M; Shonukan OO; Sledge GW; Miller KD
Invest New Drugs; 2009 Dec; 27(6):565-70. PubMed ID: 19214387
[TBL] [Abstract][Full Text] [Related]
27. β3-tubulin is a good predictor of sensitivity to taxane-based neoadjuvant chemotherapy in primary breast cancer.
Xiang Y; Yang Y; Guo G; Hu X; Zhang H; Zhang X; Pan Y
Clin Exp Med; 2016 Aug; 16(3):391-7. PubMed ID: 26088183
[TBL] [Abstract][Full Text] [Related]
28. Etirinotecan pegol (NKTR-102) versus treatment of physician's choice in women with advanced breast cancer previously treated with an anthracycline, a taxane, and capecitabine (BEACON): a randomised, open-label, multicentre, phase 3 trial.
Perez EA; Awada A; O'Shaughnessy J; Rugo HS; Twelves C; Im SA; Gómez-Pardo P; Schwartzberg LS; Diéras V; Yardley DA; Potter DA; Mailliez A; Moreno-Aspitia A; Ahn JS; Zhao C; Hoch U; Tagliaferri M; Hannah AL; Cortes J
Lancet Oncol; 2015 Nov; 16(15):1556-1568. PubMed ID: 26482278
[TBL] [Abstract][Full Text] [Related]
29. Taxane effect in a bladder washing.
Dustin SM; Jeffus SK; Stelow EB
Diagn Cytopathol; 2015 Jan; 43(1):32-3. PubMed ID: 24644138
[No Abstract] [Full Text] [Related]
30. Survival following the documentation of platinum and taxane resistance in ovarian cancer.
Büyükçelik A; Yalçin B; Utkan G; Doruk H
Gynecol Oncol; 2004 Dec; 95(3):774-5; author reply 775-6. PubMed ID: 15582006
[No Abstract] [Full Text] [Related]
31. Capecitabine after anthracycline and taxane exposure in HER2-negative metastatic breast cancer patients: response, survival and prognostic factors.
Gilabert M; Bertucci F; Esterni B; Madroszyk A; Tarpin C; Jacquemier J; Extra JM; Viens P; Gonçalves A
Anticancer Res; 2011 Mar; 31(3):1079-86. PubMed ID: 21498742
[TBL] [Abstract][Full Text] [Related]
32. [Efficacy of trastuzumab alone therapy was compared to trastuzumab plus taxane therapy in patients of advanced and metastatic breast cancers].
Sakurai K; Enomoto K; Kitajima A; Tani M; Amano S
Gan To Kagaku Ryoho; 2007 Nov; 34(12):1911-3. PubMed ID: 18219850
[TBL] [Abstract][Full Text] [Related]
33. Comparison of Pathologic Response Evaluation Systems after Anthracycline with/without Taxane-Based Neoadjuvant Chemotherapy among Different Subtypes of Breast Cancers.
Lee HJ; Park IA; Song IH; Kim SB; Jung KH; Ahn JH; Ahn SH; Kim HH; Gong G
PLoS One; 2015; 10(9):e0137885. PubMed ID: 26394326
[TBL] [Abstract][Full Text] [Related]
34. HER2/CEP17 ratio and HER2 immunohistochemistry predict clinical outcome after first-line trastuzumab plus taxane chemotherapy in patients with HER2 fluorescence in situ hybridization-positive metastatic breast cancer.
Kim JW; Kim JH; Im SA; Kim YJ; Han HS; Kim JS; Lee KH; Kim TY; Han SW; Jeon YK; Oh DY; Kim TY; Park IA
Cancer Chemother Pharmacol; 2013 Jul; 72(1):109-15. PubMed ID: 23673443
[TBL] [Abstract][Full Text] [Related]
35. Pathological outcomes of HER2-positive non-metastatic breast cancer patients treated with neoadjuvant dual anti-HER2 therapy and taxane: An Australian experience.
Choi JDW; Hughes TMD; Marx G; Rutovitz J; Hasovits C; Ngui NK
Asia Pac J Clin Oncol; 2020 Jun; 16(3):103-107. PubMed ID: 31218842
[TBL] [Abstract][Full Text] [Related]
36. Effectiveness and complications of anthracycline and taxane in the therapy of breast cancer: a meta-analysis.
Feng QJ; Zhang F; Huang XY; Wu ZX
Pathol Oncol Res; 2014 Jan; 20(1):179-84. PubMed ID: 23980023
[TBL] [Abstract][Full Text] [Related]
37. Comparison of three adjuvant chemotherapy regimes using an extended log-logistic model in women with operable breast cancer.
Faradmal J; Kazemnejad A; Khodabakhshi R; Gohari MR; Hajizadeh E
Asian Pac J Cancer Prev; 2010; 11(2):353-8. PubMed ID: 20843115
[TBL] [Abstract][Full Text] [Related]
38. Taxane-based regimens as a risk factor for chemotherapy-induced amenorrhea.
Najafi S; Djavid GE; Mehrdad N; Rajaii E; Alavi N; Olfatbakhsh A; Najafi M; Bahrami A; Heidari K
Menopause; 2011 Feb; 18(2):208-12. PubMed ID: 21037487
[TBL] [Abstract][Full Text] [Related]
39. Tau proteins expressions in advanced breast cancer and its significance in taxane-containing neoadjuvant chemotherapy.
Li ZH; Xiong QY; Tu JH; Gong Y; Qiu W; Zhang HQ; Wei WS; Hou YF; Cui WQ
Med Oncol; 2013; 30(3):591. PubMed ID: 23681778
[TBL] [Abstract][Full Text] [Related]
40. Loss of bladder sensation following taxane therapy.
Shah-Khan F; Shah P
Chemotherapy; 2008; 54(6):425-6. PubMed ID: 18824848
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
